What is the progress of the implementation of the national talks? Summaries from all over the world are coming!

People's Daily health client reporter Yao Xinran

The 2022 edition of the National Medical Insurance Drug Catalogue will be implemented from March 1, and as of February 25, Jiangsu, Guangdong, Shaanxi, Gansu, Shanghai and Hunan have issued relevant landing policies and announcements.

Gansu

On February 25, the Gansu Provincial Medical Insurance Bureau issued a notice on the implementation of the classification results of drugs (including bidding drugs) negotiated in the 2022 drug list. The notice clarifies that in order to improve the supply guarantee level of negotiated drugs (bidding drugs), all negotiated drugs (bidding drugs) during the agreement period in Gansu Province are included in the "dual-channel" management.

In 2022, 363 negotiated drugs (including bidding drugs) in the drug list were included in the separate payment management and 216 were managed according to conventional Category B. After organizing expert demonstration, the 108 new negotiated drugs (including bidding drugs) were included in the separate payment management of 39 and 69 were managed according to conventional Class B.

All localities are required to supervise the designated pharmaceutical institutions in their jurisdictions to "collect and dispense" negotiated drugs (including bidding drugs) to ensure that the 108 new negotiated drugs (including bidding drugs) in their jurisdictions are fully covered. By the end of 2023, each county (district) will have at least one designated retail pharmacy for negotiated drugs to ensure the supply of negotiated drugs (including bidding drugs).

Inner Mongolia Autonomous Region

On February 24, the Medical Insurance Bureau of Inner Mongolia Autonomous Region issued the Notice on the Implementation of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022).

The Notice clarifies that drugs negotiated by the state must be directly listed on the centralized drug procurement platform of the autonomous region by the end of February 2023 to ensure the supply of drugs. By the end of February 2023, each coordinating region should organize designated medical institutions to do a good job of catalog comparison to ensure that the new drug list is implemented on time. All drugs negotiated by the state are included in the "dual-channel" management of the autonomous region (including varieties whose prices under the generic name of bidding drugs are not higher than the payment standard). The national "2022 Drug Catalog" and the new outpatient special drugs and "dual-channel" management drugs in the autonomous region will be officially implemented from March 1, 2023. All localities should complete the construction and application of the electronic prescription center of the national medical insurance information platform by September 30, 2023, and realize the "dual-channel" electronic circulation of prescriptions.

Hunan

On February 24, the Hunan Provincial Medical Insurance Bureau issued a notice on the implementation of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022).

The 2022 Drug Catalogue contains a total of 2,967 Western medicines and proprietary Chinese medicines, including 1,586 Western medicines and 1,381 proprietary Chinese medicines. In addition, there are 892 kinds of Chinese medicine pieces that can be paid for by the fund. The state has added and transferred some drugs on the basis of the 2021 version of the catalog, and the names and limited payment scope of some drugs have been standardized and revised. During the agreement period, if a drug with the same generic name as the negotiated drug is listed, the online price shall not be higher than the medical insurance payment standard of the same specification determined by the negotiation.

All the newly added "drugs during the agreement period" drugs (including bidding drugs) are included in the "dual-channel" management scope of designated medical institutions and designated retail pharmacies in Hunan Province, and are implemented in accordance with the current inpatient, general outpatient and outpatient chronic disease treatment policies.

Jiangxi

On February 24, the Jiangxi Provincial Medical Insurance Bureau issued a notice on the implementation of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022).

Classify and manage 108 new drugs in the 2022 national medical insurance negotiation (bidding), of which 8 drugs will be included in the dual-channel A management; 16 drugs were included in the dual-channel category B management; 84 drugs are managed according to Category C and are not included in the dual-channel management scope of Jiangxi Province. The classification of 20 former national medical insurance negotiated drugs that will be converted to regular access by national medical insurance in 2022 will be adjusted, of which 4 rare disease drugs retain the original dual-channel classification management policy, and the remaining 16 withdraw from dual-channel management in Jiangxi Province.

Shanghai

On February 23, the Shanghai Pharmaceutical Centralized Bidding and Procurement Administration issued the Notice on Carrying out the Work of Listing New Drugs to the 2022 National Medical Insurance Catalog, and the new medical insurance negotiations (including bidding drugs) and the new medical insurance catalogue drugs were pushed to hospitals by the "Shanghai Pharmaceutical Procurement Service and Regulatory Information System" on February 7, 2023, effective February 10, 2023.

Guangdong

On February 23, the Guangdong Provincial Medical Insurance Bureau announced that the scope of "dual-channel" management drugs in 2023 clarified the 2023 version of the Guangdong Province Medical Insurance Drug Catalog, which included a total of 6,294 drugs, including 1,586 Western medicines, 1,381 Chinese proprietary medicines, 1,655 Chinese medicine tablets, and 1,672 hospital preparations.

There are a total of 399 drugs under the "dual-channel" management in Guangdong Province in 2023, an increase of 108 compared with the 2022 version, mainly including all national medical insurance negotiated drugs and bidding drugs during the agreement period in the "Guangdong Province Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2023 Edition)", and drugs that were included in the scope of Guangdong Province's "dual-channel" management drugs to Class B management.

Jiangsu

On February 23, Jiangsu issued the "Announcement on Publicizing the Information on the Inclusion of New National Negotiated Drugs into Our Province's Dual-channel Separate Payment Drugs in 2022", and the drugs announced this time include: 33 newly negotiated drugs dual-channel management and separate payment drugs; 73 new dual-channel drugs; 11 drugs were transferred out that were paid separately but retained for dual-channel management.

Jiangsu is currently announcing 93 new dual-channel management and separate payment drugs for negotiation, and 11 drugs with separate payment and retention of separate payment.

Xinjiang

On February 23, the Xinjiang Uygur Autonomous Region Medical Insurance Bureau issued a notice on the implementation of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022), stating that the centralized drug procurement agencies of the autonomous region and the XPCC should directly list the negotiated drugs on the centralized drug procurement platform by the end of February 2023. The price of negotiated drugs on the net is not higher than the payment standard. Enterprises participating in the catalogue access auction shall not be higher than the quotation at the time of participation in the auction during the validity period of the payment standard.